The outcome of children requiring admission to an intensive care unit following bone marrow transplantation.
We report the results of a retrospective study of the role of intensive care unit (ICU) admission in the management of 367 children who underwent bone marrow transplantation (BMT) at a tertiary referral institution. 39 patients (11%) required 44 ICU admissions for a median of 6 d. 70% received marrow from unrelated donors, half of which were mismatched; 80% had leukaemia and two-thirds were considered high-risk transplants. Respiratory failure was the major reason for admission to ICU. 75% of admissions required mechanical ventilation (for a median of 5 d) and 20 patients had lung injury as defined by the criteria of the Seattle group. None of 11 patients with proven viral pneumonitis survived (P = 0.06) and only one of 20 patients with lung injury survived (P < 0.01). Six of seven patients with a primary neurological problem survived (P < 0.001); these appear to represent a good outcome group. Age, the presence of graft-versus-host disease, the use of inotropes, isolated renal or hepatic impairment, and paediatric risk of mortality (PRISM) score were not predictive of outcome. In total, 12 patients (27% of admissions) survived and were discharged from hospital 30d or more after admission and eight (18%) survived >6 months. ICU admission can be beneficial to selected children post-BMT but it may be less useful in proven viral pneumonitis. Where mechanical ventilation is required, the duration of this support should be limited unless there is rapid improvement.
Department of Paediatric Intensive Care, Bristol Royal Hospital for Sick Children.
C
C
Hayes
R J
RJ
Lush
J M
JM
Cornish
A M
AM
Foot
J
J
Henderson
I
I
Jenkins
P
P
Murphy
A
A
Oakhill
D H
DH
Pamphilon
C G
CG
Steward
P
P
Weir
A
A
Wolf
D I
DI
Marks
D000208:Acute Disease; D000293:Adolescent; D000741:Anemia, Aplastic / Q000628:therapy; D016026:Bone Marrow Transplantation / Q000401:mortality*; D002648:Child; D002675:Child, Preschool; D003422:Critical Care; D005260:Female; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000628:therapy; D008171:Lung Diseases / Q000209:etiology / Q000628:therapy; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D011379:Prognosis; D012017:Referral and Consultation; D012121:Respiration, Artificial; D012189:Retrospective Studies; D012307:Risk Factors; D017741:Survivors